(Q34839654)

English

Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

hospitalization

1 reference

based on heuristic

inferred from title

author name string

Dan L Stewart

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Kellie J Ryan

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Jerry G Seare

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Brett Pinsky

4

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Laura Becker

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Michael Frogel

6

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

publication date

19 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

BMC Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

334

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

19 July 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3727980

8 July 2018

A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3727980

8 July 2018

Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3727980

8 July 2018

Compliance with RSV prophylaxis: Global physicians' perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3727980

8 July 2018

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3727980

8 July 2018

Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3727980

8 July 2018

Respiratory syncytial virus and parainfluenza virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3727980

8 July 2018

Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3727980

8 July 2018

Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Joint policy statement--guidelines for care of children in the emergency department

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Healthcare costs within a year of respiratory syncytial virus among Medicaid infants

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Respiratory syncytial virus testing during bronchiolitis episodes of care in an integrated health care delivery system: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Compliance with prophylaxis for respiratory syncytial virus infection in a home setting

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-334

21 January 2018

Respiratory syncytial virus activity - United States, July 2008-December 2009.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3727980

26 October 2018

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23870086

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors predicting compliance with palivizumab in high-risk infants

1 reference

https://pubmed.ncbi.nlm.nih.gov/23870086

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2334-13-334

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34839654&oldid=2197061433"